Can I Take Calcium with Duavee? What Every Woman Needs to Know

The Short Answer on Calcium and Duavee

Calcium and Duavee do not have a clinically meaningful pharmacokinetic interaction with each other. You do not need to separate them by hours for Duavee's sake. The more important concern is what else you are taking alongside them. Calcium is a notorious absorption disruptor for levothyroxine, certain antibiotics, and oral bisphosphonates, so if any of those drugs are in your cabinet, the two-hour separation rule applies to those drugs, not to Duavee specifically.

The combination of Duavee plus adequate calcium and vitamin D is actually the intended clinical strategy for menopausal bone protection, and the SMART-5 trial was designed with participants maintaining calcium and vitamin D intake throughout.

What Is Duavee and Who Is It For?

Duavee is a fixed-dose combination of conjugated estrogens 0.45 mg and bazedoxifene 20 mg approved by the FDA in 2013. It belongs to a class called tissue-selective estrogen complexes (TSECs). The estrogen component treats hot flashes and night sweats. Bazedoxifene, a selective estrogen receptor modulator (SERM), replaces the progestogen that a uterus-intact woman would otherwise need to protect her endometrium from unopposed estrogen.

Why the Uterus-Intact Distinction Matters

Women who still have a uterus cannot take estrogen alone because unopposed estrogen raises endometrial cancer risk. Traditional hormone therapy pairs estrogen with a progestogen. Duavee pairs it with bazedoxifene instead, which blocks estrogen's stimulatory effect on the uterine lining while leaving estrogen free to act on bone, the vasomotor system, and other tissues. This architecture is unique to Duavee among currently approved U.S. Menopausal hormone therapies.

Osteoporosis Prevention, Not Treatment

Duavee's FDA label specifies it for osteoporosis prevention, not treatment of established osteoporosis. If your DXA scan already shows a T-score of -2.5 or lower, a different agent, such as an oral bisphosphonate, denosumab, or romosozumab, is typically warranted. Ask your clinician which category you fall into before assuming Duavee covers your bone needs fully.

Understanding the Calcium Interaction (or Lack Thereof)

Pharmacokinetics: Does Calcium Change How Duavee Is Absorbed?

Pharmacokinetic interaction studies submitted to the FDA for Duavee did not show clinically significant changes in conjugated estrogen or bazedoxifene exposure when calcium carbonate was co-administered. Bazedoxifene reaches peak plasma concentration (Tmax) in approximately two hours and is not meaningfully chelated by calcium ions the way tetracycline antibiotics or fluoroquinolones are. Conjugated estrogens are similarly unaffected by calcium at standard supplement doses.

This contrasts with drugs that form insoluble complexes with divalent cations. Calcium carbonate, for instance, raises gastric pH transiently, which could theoretically affect drugs that require acidic conditions for dissolution, but bazedoxifene's absorption profile does not depend on a low-pH environment to any clinically relevant degree.

Pharmacodynamics: Calcium and Duavee Work Together on Bone

The interaction here is additive and beneficial. Duavee reduces bone resorption by suppressing osteoclast activity through estrogenic signaling. Calcium provides the raw mineral substrate that osteoblasts need to build new bone matrix. Without adequate calcium, estrogen's bone-preserving signal has less material to work with. The SMART-5 trial enrolled postmenopausal women aged 40 to 75 and required all participants to take 600 to 1,200 mg of elemental calcium plus 200 to 400 IU of vitamin D daily. Lumbar spine bone mineral density increased by approximately 1.51% with Duavee versus a loss of 0.35% with placebo at 12 months, a result that assumed baseline calcium adequacy.

The Real Interaction Risk: Other Drugs in Your Regimen

Calcium's absorption-blocking properties are documented for several drugs that menopausal women commonly take:

• Levothyroxine: Calcium carbonate reduces levothyroxine absorption by up to 20 to 40% when taken together. Separate by at least four hours.
• Oral bisphosphonates (alendronate, risedronate): These must be taken on an empty stomach with plain water. Calcium taken within 30 to 60 minutes significantly reduces bisphosphonate bioavailability.
• Iron supplements: Calcium competes with iron for intestinal transport. Separate by at least two hours if you are treating iron-deficiency anemia, which remains common in perimenopausal women due to heavy menstrual bleeding.
• Certain antibiotics: Fluoroquinolones and tetracyclines chelate with calcium. If you are prescribed ciprofloxacin or doxycycline, take calcium at a separate time.

A practical rule: Duavee does not need to be separated from calcium. Everything else in your medicine cabinet might.

How Much Calcium Do You Actually Need at Menopause?

The National Academies of Sciences, Engineering, and Medicine set the recommended dietary allowance (RDA) for calcium at 1,000 mg per day for women aged 19 to 50 and 1,200 mg per day for women aged 51 and older. Most postmenopausal women in the United States fall short of this target from diet alone, averaging roughly 800 mg per day from food.

Food First, Supplement Second

Dietary calcium comes with co-factors, including protein, lactose, and organic acids, that improve absorption. Calcium from food is absorbed at approximately 30 to 35% efficiency versus 25 to 30% for calcium carbonate supplements. Good dietary sources include:

• Plain whole-milk yogurt: approximately 300 mg per cup
• Firm tofu (made with calcium sulfate): 250 to 350 mg per half-cup
• Canned sardines with bones: approximately 325 mg per 3 oz
• Fortified plant milks: 300 to 450 mg per cup (check the label)
• Cooked collard greens: approximately 260 mg per cup

If diet provides 700 to 800 mg, a single 500 mg supplement dose covers the gap. You do not need to exceed 500 to 600 mg in a single supplement dose because intestinal absorption saturates above that threshold, meaning a 1,200 mg tablet is not better than two 600 mg tablets taken four to six hours apart.

Calcium Carbonate vs. Calcium Citrate: Which Form?

Calcium carbonate (Caltrate, Os-Cal, Tums) is cheapest and most widely available but requires stomach acid for dissolution. It is best taken with food. If you take a proton pump inhibitor (omeprazole, pantoprazole) for reflux, calcium carbonate absorption may be reduced, and calcium citrate is preferred because it dissolves independently of gastric pH. Calcium citrate (Citracal) is also a better choice if you have a history of kidney stones, because it reduces urinary oxalate excretion.

Vitamin D: The Calcium Co-Factor You Cannot Ignore

Calcium absorption depends on vitamin D. Without adequate 25-hydroxyvitamin D levels, intestinal calcium absorption falls to as low as 10 to 15%. The Endocrine Society recommends 1,500 to 2,000 IU of vitamin D3 daily for adults at risk of deficiency, which includes most postmenopausal women with limited sun exposure. The SMART-5 trial used 200 to 400 IU, a dose now considered by many clinicians to be on the lower end of adequacy, so discuss your personal serum 25(OH)D level with your provider.

A 25(OH)D level of at least 30 ng/mL (75 nmol/L) is generally considered sufficient for bone health, though some endocrinologists target 40 to 60 ng/mL. If you are on Duavee for bone protection and your vitamin D is deficient, you are undermining the drug's intended effect.

Sex-Specific Physiology: Why Bone Loss Accelerates After Menopause

Estrogen is the primary regulator of bone turnover in women. In the years before and after your final menstrual period, estrogen levels drop from roughly 100 to 150 pg/mL to below 20 pg/mL, a fall that removes the brake on osteoclast activity. Bone resorption outpaces formation for approximately five to seven years after menopause, with women losing an average of 1 to 2% of bone mass per year during this window. Some women lose up to 3 to 5% per year.

Men lose bone too, but more slowly and without the sharp hormone-withdrawal inflection point. This is why osteoporosis disproportionately affects women and why every woman approaching menopause deserves a conversation about calcium intake, vitamin D status, weight-bearing exercise, and, where appropriate, pharmacological support.

Perimenopause vs. Postmenopause: Different Calcium Needs, Different Drug Options

Duavee is approved only for postmenopausal women. If you are in perimenopause, defined as the years before your final period when cycles become irregular and FSH begins to rise, Duavee is not indicated. During perimenopause:

• Calcium and vitamin D optimization is appropriate at any age.
• Combined hormonal contraceptives can manage both cycle irregularity and provide some estrogen exposure for bone.
• Bone loss is beginning but is usually not yet at the rate seen in early postmenopause.

Once you have had 12 consecutive months without a period, you are postmenopausal and Duavee becomes an option if you have hot flashes or concern about bone density and you have a uterus.

Pregnancy, Lactation, and Contraception: Required Reading

Duavee is contraindicated in pregnancy. The FDA label carries a black-box warning: estrogens and progestogens should not be used during pregnancy. Bazedoxifene is a SERM with unknown teratogenic potential in humans; animal studies showed fetal abnormalities at high doses. If you are pregnant or think you might be, stop Duavee immediately and contact your clinician.

Duavee is not a contraceptive. It does not suppress ovulation. If you are in perimenopause and still having cycles, even irregular ones, pregnancy is possible. You must use a reliable contraceptive method alongside Duavee if there is any chance of conception, or confirm with your clinician that you meet the 12-month amenorrhea criterion for postmenopause.

Lactation: Duavee is not approved for use in premenopausal or reproductive-age women and should not be used during breastfeeding. Conjugated estrogens transfer into breast milk and can suppress lactation. Bazedoxifene transfer into human milk has not been studied.

Calcium during pregnancy and lactation is, by contrast, not only safe but necessary. Pregnant women need 1,000 mg of elemental calcium daily (1,300 mg if under age 18). Lactating women need 1,000 mg. These are unrelated to Duavee, which you would not be taking during those life stages.

Who This Is Right For and Who Should Reconsider

Women Who May Benefit Most from Duavee Plus Calcium

• Postmenopausal women with a uterus who have moderate to severe hot flashes and want concurrent bone protection without adding a progestogen.
• Women who experienced mood-related or physical side effects from progestogens (medroxyprogesterone acetate, micronized progesterone) in standard hormone therapy.
• Women with low bone density (T-score between -1.0 and -2.5, classified as osteopenia) who are not yet candidates for bisphosphonate therapy.
• Women who cannot tolerate or prefer to avoid bisphosphonates due to gastrointestinal side effects or adherence challenges.

Women Who Should Use a Different Approach

• Women without a uterus (hysterectomy): estrogen alone is the preferred option and bazedoxifene adds no uterine-protection benefit.
• Women with established osteoporosis (T-score -2.5 or lower or a prior fragility fracture): Duavee is not approved for treatment at this severity. An anabolic or antiresorptive agent with a stronger evidence base is warranted.
• Women with a personal or strong family history of breast cancer: the SMART trials excluded women at high breast cancer risk, and The Menopause Society advises individualized risk assessment.
• Women with unexplained vaginal bleeding, known or suspected estrogen-dependent cancers, active DVT or PE, or liver disease: all are contraindications per the FDA label.

Cardiovascular Considerations: The Calcium Debate in Menopausal Women

A separate, ongoing conversation in women's health concerns whether calcium supplements (as opposed to dietary calcium) raise cardiovascular risk. The Women's Health Initiative calcium plus vitamin D trial found no significant increase in myocardial infarction overall, though a subgroup analysis suggested a possible signal in women already taking personal calcium supplements at enrollment. Subsequent meta-analyses have produced conflicting results.

The Menopause Society's 2022 position statement on nonhormone therapies does not restrict calcium supplementation but recommends keeping total daily intake below 2,000 to 2,500 mg from all sources to avoid potential adverse effects, including hypercalcemia and kidney stones. The practical takeaway: get as much calcium as possible from food, use the smallest supplement dose needed to close the gap, and do not stack multiple calcium-containing supplements without counting the total.

Duavee itself has not been shown to modify the potential cardiovascular signal from calcium supplements. The two substances operate through entirely separate mechanisms on the heart and vasculature.

Monitoring: What to Track When You Take Both

If you are on Duavee and taking calcium and vitamin D, a reasonable monitoring schedule includes:

• Serum 25(OH)D: at baseline and after three to six months of supplementation to confirm you have reached the target range.
• DXA scan: at baseline when starting Duavee for bone prevention, repeated at one to two years depending on your baseline T-score and clinical risk factors. The National Osteoporosis Foundation recommends repeat DXA no more frequently than every two years in most women on stable therapy.
• Serum calcium: not routinely necessary at standard supplement doses, but worth checking if you develop symptoms of hypercalcemia (fatigue, constipation, increased thirst, confusion) or if you take thiazide diuretics, which reduce urinary calcium excretion and can raise serum calcium.
• Urinary calcium (24-hour collection): indicated if you have a personal history of calcium oxalate kidney stones before increasing supplementation.
• Mammogram and endometrial surveillance: per standard menopausal hormone therapy guidelines. The American College of Obstetricians and Gynecologists recommends annual breast cancer screening for women on hormone therapy.

Practical Timing: A Daily Schedule That Works

Here is a sample daily schedule for a woman taking Duavee, levothyroxine, calcium, and vitamin D:

| Time | Action | |------|---------| | 6:00 AM | Levothyroxine on an empty stomach with water only | | 7:00 AM | Breakfast | | 7:00 AM | Duavee with or without food (take consistently) | | 10:00 AM | Calcium carbonate 500 mg + vitamin D with a snack | | 10:00 AM | (Minimum 4 hours after levothyroxine) | | 5:00 PM | Second calcium dose 500 mg with dinner if needed |

This schedule respects the levothyroxine-calcium separation without requiring you to space Duavee from anything. If you take calcium citrate instead of carbonate, you have more flexibility because citrate does not depend on food-stimulated acid secretion.

A Note on PCOS and Premature Ovarian Insufficiency

Women with polycystic ovary syndrome (PCOS) face a complicated hormonal picture that affects bone health differently. Chronically elevated androgens and irregular cycles in PCOS create variable estrogen exposure across the reproductive years. Women with PCOS who reach menopause may have different baseline bone density trajectories than the general population, though the data are not fully characterized. Duavee has not been studied specifically in women with a PCOS history.

Women with premature ovarian insufficiency (POI), defined as ovarian failure before age 40, face an even more pressing bone-protection need because they spend decades in a low-estrogen state before conventional menopause age. For POI, the ESHRE guideline on premature ovarian insufficiency recommends hormone therapy continued until at least the average age of natural menopause (around 51 years). Duavee has not been studied in POI and is not currently standard of care in that population. Calcium and vitamin D optimization is appropriate regardless of which hormone therapy regimen a woman with POI uses.

The Evidence Gap: What We Do Not Yet Know

Women have been underrepresented in pharmacokinetic interaction studies, and most calcium-drug interaction data come from studies conducted predominantly in male subjects or in mixed-sex populations where female-specific results were not reported separately. The SMART trials enrolled only women, which is a strength for Duavee-specific data, but calcium interaction studies in the Duavee FDA package used limited sample sizes. The absence of a significant interaction signal in those studies is reassuring but does not constitute the same evidence quality as a large, dedicated interaction trial.

For women of color, data are even thinner. Black women have on average higher bone density than white women but are underdiagnosed for osteoporosis and undertreated once diagnosed. NHANES data show Black women also have higher rates of vitamin D deficiency due to reduced cutaneous synthesis from higher skin melanin content. If you are a Black woman on Duavee, insist on a baseline 25(OH)D level and a DXA scan rather than assuming lower baseline risk means no monitoring is needed.